Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 study of unesbulin plus dacarbazine in unresectable or metastatic, relapsed or refractory leiomyosarcoma
2022-000073-12Phase 2Terminated
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in leiomyosarcoma (LMS) comparing Unesbulin + dacarbazine with Placebo + dacarbazine (2 arms). Primary endpoint: Progression-free survival (PFS). Started Apr 2022; status: terminated.
02
Drugs
unesbulin
03
Conditions
leiomyosarcoma (LMS)
Beyond the preview
Go deeper on 2022-000073-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000073-12.